Header

Cutaneous Skin Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 8 trials

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Group 1) or with unresectable locally advanced CSC...

Diagnosis: Cutaneous Skin Cancer

Phase: 2

Protocol Number: 16-220

Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

This partially randomized phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with v-raf murine sarc...

Diagnosis: Cutaneous Skin Cancer

Phase: 1 / 2

Protocol Number: 13-424

A Study of DCC-2701 in Participants With Advanced Solid Tumors

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to ...

Diagnosis: Cutaneous Skin Cancer

Phase: 1

Protocol Number: 14-031

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

This is a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy to dabrafenib administered with a trametinib placebo...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 12-277

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 14-332

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 15-217

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes...

Diagnosis: Cutaneous Skin Cancer, Other Trials

Phase:

Protocol Number: 16-388

'